Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;47(4):667-674.
doi: 10.1111/ced.15019. Epub 2021 Dec 19.

The role of thalidomide in dermatology

Affiliations
Review

The role of thalidomide in dermatology

K Hussain et al. Clin Exp Dermatol. 2022 Apr.

Abstract

Thalidomide is a medication that has been in existence for over half a century, and has proven to be useful and effective in severe dermatological conditions. For dermatologists, the ability of thalidomide to reduce the levels of the cytokine tumour necrosis factor-α, along with its immunomodulatory and anti-angiogenic properties, is of great significance, with the added advantage of being an oral medication. Its use is of course strictly monitored, owing to its potential adverse effects (AEs), particularly teratogenicity, with precautions taken to ensure its safe and correct use by both prescriber and patient. In this review, we look at the background and mechanism of action of thalidomide, provide an overview of conditions it can be used for with case examples, explain the potential AEs and monitoring requirements, and discuss future developments.

PubMed Disclaimer

Comment in

References

    1. Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 2015; 105: 140-56.
    1. Faver IR, Guerra SG, Su WPD, El-Azhary R. Thalidomide for dermatology: a review of clinical uses and adverse effects. Int J Dermatol 2005; 44: 61-7.
    1. Lenz W. Thalidomide and congenital abnormalities. In: Problems of Birth Defects, vol. 199. (Persaud TVN ed). Netherlands: Springer, 1962.
    1. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; ii: 90927-8.
    1. Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.